Resources Archive - Page 28 of 46

CD34+ Hematopoietic Stem Cell Differentiation Platform

To accelerate screening and lead optimization efforts involving immune cell differentiation, WuXi AppTec offers a comprehensive CD34+ hematopoietic stem cell...

Inhibition of the hERG potassium ion channel by non-nucleoside CMV polymerase antiviral inhibitors

WuXi AppTec scientists collaborated on a study to characterize a series of pyrroloquinoline derivatives that were designed and synthesized to...

TEAD Proteins Associate With DNA Repair Proteins to Facilitate Cellular Recovery

WuXi AppTec scientists recently contributed to a research study which utilized an affinity purification mass spectrometry approach to identify nuclear...

AACR 2023: Comparison of two DTH models for T cell-mediated immunity

To characterize the immunity profile of the most widely used delayed-type hypersensitivity (DTH) models, WuXi AppTec scientists built 2,4-dinitrofluorobenzene (DNFB)...

Enzalutamide-resistant LNCaP ARF877L Mutation KI model

We have established an enzalutamide-resistant (LNCaP AR-F877L mutation) KI prostate cancer model to support the development of next-generation therapeutics. An...

Recent Advances in Library Synthesis to Accelerate Medicinal Chemistry Research

Learn how parallel medicinal chemistry (PMC) and high-throughput experimentation (HTE) can provide a more focused approach to target molecules, resulting...

Gout Models

As part of our autoimmune and inflammatory disease platform, we provide an extensive panel of monosodium urate (MSU) induced gout...

Drug Resistant Models

Comprehensive portfolio of drug resistant models representing clinically relevant mechanisms of resistance: 10+ cancer types 25+ key targets 30+ leading...

Cancer Pharmacology Services

Offering a wide range of targeted oncology services and translational models. Our comprehensive platform includes: in vitro biochemical, biophysical, and...

Knowledge Library